Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis

Archives of Ophthalmology

Volumn 122, Issue 6, 2004, Pages 845-851

  Murphy, Conor C ^a   Greiner, Kathrin ^b   Plskova, Jarka ^b   Duncan, Linda ^b   Frost, Andrew ^a   Isaacs, John D ^c   Rebello, Peppy ^d   Waldmann, Herman ^d   Hale, Geoff ^d   Forrester, John V ^b   Dick, Andrew D ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; P55 TUMOR NECROSIS FACTOR RECEPTOR FUSION PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ARTICLE; BINOCULAR INDIRECT OPHTHALMOSCOPY SCORE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HAZE; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATION; INFUSION; LOGMAR VISUAL ACUITY; LONG TERM CARE; LYMPHOCYTOPENIA; MALE; NAUSEA; NONINFECTIOUS POSTERIOR UVEITIS; OPEN STUDY; OUTCOMES RESEARCH; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REMISSION; RETINA MACULA CYSTOID EDEMA; SCORING SYSTEM; URTICARIA; UVEITIS; VERTIGO; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HAZE;

ADULT; FEMALE; HUMANS; IMMUNOGLOBULIN GAMMA-CHAINS; IMMUNOGLOBULIN HEAVY CHAINS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OPHTHALMOSCOPY; PILOT PROJECTS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SAFETY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS, POSTERIOR; VISUAL ACUITY;

EID: 2942592723     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.6.845     Document Type: Article

References (41)

1. Forrester JV. Uveitis: pathogenesis. Lancet. 1991;338:1498-1501.
2. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80:844-848.
3. Dick AD, Azim M, Forrester JV. Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A. Br J Ophthalmol. 1997;81:1107-1112.
4. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513.
5. Forrester JV. Duke-Elder Lecture: new concepts on the role of autoimmunity in the pathogenesis of uveitis. Eye. 1992;6(pt 5):433-446.
6. Caspi RR, Sun B, Agarwal RK, et al. T cell mechanisms in experimental autoimmune uveoretinitis: susceptibility is a function of the cytokine response profile. Eye. 1997;11(pt 2):209-212.
7. Nakamura S, Yamakawa T, Sugita M, et al. The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci. 1994;35:3884-3889.
8. Sartani G, Silver PB, Rizzo LV, et al. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci. 1996;37:2211-2218.
9. Kijlstra A. Cytokines: their role in uveal disease. Eye. 1997;11(pt 2):200-205.
10. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251-255.
11. Palexas GN, Sussman G, Welsh NH. Ocular and systemic determination of IL-1 beta and tumour necrosis factor in a patient with ocular inflammation. Scand J Immunol Suppl. 1992;11:173-175.
12. Dick AD, McMenamin PG, Korner H, et al. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol. 1996;26:1018-1025.
13. Dick AD, Duncan L, Hale G, Waldmann H, Isaacs J. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun. 1998;11:255-264.
14. Robertson M, Liversidge J, Forrester JV, Dick AD. Neutralizing tumor necrosis factor-α activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2003;44:3034-3041.
15. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141-147.
16. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105-1110.
17. Lipsky PE, van der Heijde DM, St Clair EW, et al. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594-1602.
18. Targan SR, Hanauer SB, van Deventer SJ, et al. Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med. 1997;337:1029-1035.
19. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet. 2001;358:295-296.
20. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med. 1991;174:1483-1489.
21. Cobbold SP, Rebello PR, Davies HF, Friend PJ, Clark MR. A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants. J Immunol Methods. 1990;127:19-24.
22. Rebello PR, Hale G, Friend PJ, Cobbold SP, Waldmann H. Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation. 1999;68:1417-1420.
23. Benezra D, Forrester J, Nussenblatt R, Tabbara K, Timonen P. Uveitis Scoring System. Berlin, Germany: Springer-Verlag; 1991.
24. Chylack LT Jr, Wolfe JK, Singer DM, et al, the Longitudinal Study of Cataract Study Group. The Lens Opacities Classification System III. Arch Ophthalmol. 1993;111:831-836.
25. Jenkinson C, Layte R, Wright L, Coulter A. The UK-SF-36: An Analysis and Interpretation Manual. Oxford, England: Joshua Horgan Print Partnership; 1996.
26. Frost NA, Sparrow JM, Durant JS, Donovan JL, Peters TJ, Brookes ST. Development of a questionnaire for measurement of vision-related quality of life. Ophthalmic Epidemiol. 1998;5:185-210.
27. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/ II clinical trial. Proc Natl Acad Sci U S A. 1999;96:7462-7466.
28. Dick AD, Isaacs JD. Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium. Br J Ophthalmol. 1999;83:1230-1234.
29. Dick AD, Meyer P, James T, et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol. 2000;84:107-109.
30. Waldmann H, Cobbold S. How do monoclonal antibodies induce tolerance? a role for infectious tolerance? Annu Rev Immunol. 1998;16:619-644.
31. Gardiner AM, Armstrong RA, Dunne MC, Murray PI. Correlation between visual function and visual ability in patients with uveitis. Br J Ophthalmol. 2002;86:993-996.
32. Spencer-Green G. Etanercept (Enbrel): update on therapeutic use. Ann Rheum Dis. 2000;59(suppl 1):i46-i49.
33. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999;13(suppl 4):16-22; discussion, 38.
34. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
35. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411-452.
36. Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000;43:1346-1352.
37. Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001;44:1411-1415.
38. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352-356.
39. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121:437-440.
40. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995;83:793-802.
41. Ruuls SR, Hoek RM, Ngo VN, et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity. 2001;15:533-543.